Is Sesamol Effective in Corneal Neovascularization?

Area of Science:

• Ophthalmology
• Pharmacology
• Angiogenesis Research

Background:

• Corneal neovascularization (CNV) is a pathological process involving new blood vessel growth.
• CNV can lead to vision impairment and is often associated with inflammation or injury.
• Current treatments for CNV have limitations, necessitating the exploration of novel therapeutic agents.

Purpose of the Study:

• To investigate the antiangiogenic potential of sesamol in a rat model of chemically induced corneal neovascularization.
• To compare the efficacy of topical versus subconjunctival administration of sesamol.
• To evaluate the combined effect of sesamol and bevacizumab on corneal neovascularization.

Main Methods:

• Experimentally induced corneal neovascularization in 56 Wistar Albino rats.
• Administration of topical or subconjunctival sesamol, bevacizumab, or combinations.
• Control groups received Tween 80 or no treatment.
• Assessment of neovascularization using digital imaging and histological analysis (hematoxylin-eosin, CD31 staining).

Main Results:

• All treatment groups showed statistically significant reduction in corneal neovascularization compared to controls (P<0.001).
• Topical sesamol was more effective than subconjunctival sesamol (P=0.003).
• Topical sesamol combined with bevacizumab demonstrated greater efficacy than topical bevacizumab alone (P=0.018).

Conclusions:

• Sesamol exhibits significant antiangiogenic properties.
• Topical sesamol monotherapy is a potential strategy for managing corneal neovascularization.
• Combining topical sesamol with bevacizumab may offer an enhanced therapeutic approach for preventing corneal neovascularization.